Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Shah says as more treatments become available, oncologists need to consider the order in which they give treatments to patients with gastric and gastroesophageal junction cancer.
Manish A. Shah, MD, medical oncologist, Bartlett Associate Professor of GI Oncology, Weill Cornell Medical Center at NewYork-Presbyterian Hospital, discusses how BBI608 might fit into the treatment paradigm for gastric and gastroesophageal junction cancer. Shah says as more treatments become available, oncologists need to consider the order in which they give patients treatments. He adds that not all gastric cancers are the same, so identifying which cancers would be best treated by a PD-1 inhibitor and which would be best treated by a stem cell inhibitor is crucial.
Novel Approaches Focus on Limiting Toxicity in Older Patients with ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
